Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes ( TIMES 2): a 52‐week open‐label, multicenter phase 3 trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14613 ◽

2021 ◽

Author(s):

Julie Dubourg ◽

Pascale Fouqueray ◽

Damien Quinslot ◽

Jean‐Marie Grouin ◽

Kohei Kaku

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Open Label ◽

Phase 3 ◽

Antidiabetic Agents ◽

Safety And Efficacy ◽

Multicenter Phase

Download Full-text

Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study

Diabetes Obesity and Metabolism ◽

10.1111/dom.12693 ◽

2016 ◽

Vol 18 (9) ◽

pp. 925-929 ◽

Cited By ~ 33

Author(s):

K. Kaku ◽

K. Enya ◽

R. Nakaya ◽

T. Ohira ◽

R. Matsuno

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Open Label ◽

Safety And Efficacy ◽

Open Label Phase ◽

Phase Iii Study ◽

G Protein Coupled

Download Full-text

Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2018.1434145 ◽

2018 ◽

Vol 19 (4) ◽

pp. 327-336 ◽

Cited By ~ 7

Author(s):

Hiroshi Maegawa ◽

Kazuyuki Tobe ◽

Hiromi Tabuchi ◽

Ichiro Nakamura ◽

Satoshi Uno

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Japanese Patients ◽

Term Study ◽

Safety And Efficacy ◽

Long Term Study ◽

Elderly Japanese ◽

Elderly Japanese Patients

Download Full-text

Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2014.887680 ◽

2014 ◽

Vol 15 (6) ◽

pp. 749-766 ◽

Cited By ~ 51

Author(s):

Yukio Tanizawa ◽

Kohei Kaku ◽

Eiichi Araki ◽

Kazuyuki Tobe ◽

Yasuo Terauchi ◽

...

Keyword(s):

Japanese Patients ◽

Selective Inhibitor ◽

Open Label ◽

Oral Antidiabetic Agents ◽

Antidiabetic Agents ◽

Randomized Controlled ◽

Oral Antidiabetic ◽

Sodium Glucose Cotransporter

Download Full-text

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.13856 ◽

2019 ◽

Vol 21 (12) ◽

pp. 2674-2683 ◽

Cited By ~ 4

Author(s):

Kohei Kaku ◽

Eiichi Araki ◽

Yukio Tanizawa ◽

Bue Ross Agner ◽

Tomoyuki Nishida ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomized Trial ◽

Fixed Ratio ◽

Japanese Patients ◽

Insulin Degludec ◽

Open Label ◽

Phase 3 ◽

Superior Efficacy

Download Full-text

Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes

Journal of Diabetes Investigation ◽

10.1111/j.2040-1124.2011.00137.x ◽

2011 ◽

Vol 2 (6) ◽

pp. 448-456 ◽

Cited By ~ 11

Author(s):

Nobuya Inagaki ◽

Kohjiro Ueki ◽

Ayuko Yamamura ◽

Hitoshi Saito ◽

Takeshi Imaoka

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Safety And Efficacy

Download Full-text

Efficacy and safety of nateglinide plus sitagliptin combination therapy in type 2 diabetes patients inadequately controlled by sitagliptin monotherapy: a phase 3, multicenter, open-label, long-term study

Diabetology International ◽

10.1007/s13340-017-0341-z ◽

2018 ◽

Vol 9 (3) ◽

pp. 168-178

Author(s):

Takahisa Hirose ◽

Chihiro Saitoh ◽

Ichiro Oikawa ◽

Nobuo Kondo

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Efficacy And Safety ◽

Open Label ◽

Term Study ◽

Phase 3 ◽

Long Term Study ◽

Diabetes Patients

Download Full-text

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

Journal of Diabetes Investigation ◽

10.1111/jdi.13066 ◽

2019 ◽

Vol 10 (6) ◽

pp. 1518-1526 ◽

Cited By ~ 4

Author(s):

Yasuo Terauchi ◽

Hisataka Fujiwara ◽

Yuji Kurihara ◽

Hideki Suganami ◽

Masahiro Tamura ◽

...

Keyword(s):

Receptor Agonist ◽

Japanese Patients ◽

Open Label ◽

Safety And Efficacy ◽

Sodium Glucose Cotransporter ◽

Post Marketing ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

PO433 EFFICACY AND SAFETY OF LUSEOGLIFLOZIN IN YOUNGER AND ELDERLY JAPANESE PATIENTS WITH TYPE 2 DIABETES MELLITUS: ANALYSIS OF POOLED DATA FROM LONG-TERM PHASE 3 TRIALS

Diabetes Research and Clinical Practice ◽

10.1016/s0168-8227(14)70727-2 ◽

2014 ◽

Vol 106 ◽

pp. S267

Author(s):

M. Ubukata ◽

S. Sakai ◽

Y. Samukawa ◽

T. Sasaki ◽

M. Haneda ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Pooled Data ◽

Elderly Japanese ◽

Elderly Japanese Patients

Download Full-text

Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus:post hocsubgroup analyses according to body mass index in a 52-week open-label study

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2015.1055250 ◽

2015 ◽

Vol 16 (11) ◽

pp. 1577-1591 ◽

Cited By ~ 15

Author(s):

Nobuya Inagaki ◽

Maki Goda ◽

Shoko Yokota ◽

Nobuko Maruyama ◽

Hiroaki Iijima

Keyword(s):

Type 2 Diabetes ◽

Body Mass Index ◽

Body Mass ◽

Japanese Patients ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

Journal of Diabetes Investigation ◽

10.1111/j.2040-1124.2012.00226.x ◽

2012 ◽

Vol 3 (6) ◽

pp. 517-525 ◽

Cited By ~ 24

Author(s):

Yutaka Seino ◽

Shinzo Hiroi ◽

Masashi Hirayama ◽

Kohei Kaku

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Extension Study ◽

Efficacy And Safety ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo

Download Full-text